Please login to the form below

Not currently logged in
Email:
Password:

Xceleron expands US operations

Xceleron has signed a lease on a multimillion dollar facility in the US to expand its reach in the region

UK-based drug development analytical strategies company, Xceleron, has signed a lease on a multimillion dollar facility in the state of Maryland in the US.

The facility will open in November 2007 housing a new accelerator mass spectrometer (AMS) and employing at least 20 people in scientific, commercial and administrative roles.

The move follows the establishment of Xceleron's North American business in 2005 to meet increased demand in what the company cites as a USD 1bn market worldwide for drug delivery analytics.

CEO of Xceleron, Professor Colin Garner, said: "We will invest up to USD 7.5m on the purchase of a new AMS and associated equipment to carry out analysis on pharmaceutical drug candidates. Our new facility will allow us to substantially increase our development capacity to better serve our customers worldwide."

Dr Pradeep Ganguly, director of the Montgomery County Department of Economic Development, welcomed Xceleron's decision to set up its new accelerator mass Spectrometer (AMS) in the US: "Xceleron is a highly innovative life sciences company, with a technology that will greatly advance drug discovery. We are delighted that this UK-based company has decided to expand in Germantown."

23rd July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....